期刊
ONCOLOGY REPORTS
卷 38, 期 2, 页码 899-907出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2017.5722
关键词
hepatocellular carcinoma; sorafenib resistance; PD-L1; DNMT1; DNA methylation
类别
资金
- Foundation of Jilin Provincial Development and Reform Commission [KY20160002, 3J115AJ73428]
- Jilin University Fund for Excellent Young Teacher [419080500355]
- Youth Fund from the Department of Science and Technology, Jilin Province, China [20140520026JH]
Molecule-targeted therapy, such as sorafenib, is one of the effectively therapeutic options for advanced hepatocellular carcinoma (HCC). However, acquired resistance to sorafenib has been found in some HCC patients, resulting in poor prognosis. It is reported that PD-L1 and DNA methyltransferases (DNMTs) contribute to drug resistance. In this study, by inducing sorafenib-resistant HCC cell lines, we investigated their molecular and functional characteristics. Our data indicated that highly upregulated DNMT1 was positively correlated with PD-L1 overexpression in sorafenib-resistant HCC cells. We demonstrate that PD-L1 regulate DNMT1 through STAT3 signaling pathway. Knockdown of PD-L1 induced DNMT1dependent DNA hypomethylation and restored the expression of methylation-silenced CDH1. Moreover, inactivation of NF kappa B blocked PD-L1/STAT3/DNMT1 pathway in sorafenibresistant HCC cells. Functionally, genetic or pharmacological disruption of PD-L1 or/and DNMT1 sensitize HCC resistance to sorafenib. Importantly, dual inactivation of PD-L1 and DNMT1 by their inhibitor synergistically disrupts the colony formation of sorafenib-resistant HCC cells. These results demonstrate that targeting NF kappa B/PDL1/STAT3/DNMT1 axis is a new therapeutic strategy for preventing or overcoming the acquired resistance to sorafenib in HCC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据